Home Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.7, p.497–506,2021

Journal info


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564


Aims and Scope
Editorial Info
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.122, No.7, p.497–506,2021

Title: Determination of inhibitor activity of drugs against the COVID-19
Author: M. A. Gedikli, B. Tuzun, K. Sayin, H. Ataseven

Abstract: BACKGROUND: It is the SARS-CoV-2 virus, one of the most significant diseases of today’s world. Due to the high transmission of this disease, studies are ongoing to discover an inhibitor drug that can stop this disease. In this study, inhibitory drugs used for many diseases were tried to stop the SARS-CoV-2 virus.
AIM: In the calculations made, inhibitor molecules for the SARS-CoV-2 virus were calculated by molecular docking method.
RESULTS AND CONCLUSION: Inhibitory activities of SARS-CoV-2 virus against spike glycoprotein (PDB ID: 6M0J, 6LZG), main protease (PDB ID: 5RGG, 6WTT), and RNA dependent RNA polymerase (RdRp) (PDB ID: 6YYT, 7BV2) proteins were compared. Then, docking calculations were supported by calculations by MM-PSBA of the inhibitor with the highest activity. Afterwards, it was compared with FDA approved drugs for the SARS-CoV-2 virus. It was found that the Carvedilol molecule was the best against RNA dependent RNA polymerase (RdRp) protein of SARS-CoV-2 (Tab. 4, Fig. 9, Ref. 42).

Keywords: SARS-CoV-2, molecular docking, COVID-19, ADME/T, inhibitory activities.
Published online: 23-Jun-2021
Year: 2021, Volume: 122, Issue: 7 Page From: 497, Page To: 506

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.